A phase I/II study of trimetrexate and capecitabine in patients with advanced refractory colorectal cancer

Matin, K, Jacobs, SA, Richards, T, Wong, MK, Earle, M, Evans, T, Troetschel, M, Ferri, W, Friedland, D, Pinkerton, R, Volkin, R, Wieand, S and Ramanathan, RK (2005) A phase I/II study of trimetrexate and capecitabine in patients with advanced refractory colorectal cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 28 5: 439-444. doi:10.1097/01.coc.0000170797.36351.3a


Author Matin, K
Jacobs, SA
Richards, T
Wong, MK
Earle, M
Evans, T
Troetschel, M
Ferri, W
Friedland, D
Pinkerton, R
Volkin, R
Wieand, S
Ramanathan, RK
Title A phase I/II study of trimetrexate and capecitabine in patients with advanced refractory colorectal cancer
Journal name American Journal of Clinical Oncology: Cancer Clinical Trials   Check publisher's open access policy
ISSN 0277-3732
Publication date 2005-01-01
Sub-type Article (original research)
DOI 10.1097/01.coc.0000170797.36351.3a
Volume 28
Issue 5
Start page 439
End page 444
Total pages 6
Language eng
Subject 2730 Oncology
1306 Cancer Research
Abstract Objective: We tested the hypothesis that the combination of trimetrexate (TMTX) and capecitabine (CAP) would be active in patients with previously treated metastatic colorectal cancer (CRC). Because the optimum dose of this combination was unknown, we used a phase I/II design. Methods: In the phase I cohort, patients received 110 mg/m2 TMTX intravenously weekly ×6 and CAP starting at 750 mg/m2 orally twice daily from days 2 to 15 and 23 to 36 (one cycle). Cycles were repeated every 8 weeks. The phase II doses were 110 mg/m2 TMTX and 1000 mg/m2 CAP orally twice daily. Results: Thirty-two patients were entered. All patients had prior 5-fluorouracil therapy and 94% had prior exposure to irinotecan. Grade 3/4 toxicities included abdominal pain in 4 patients (12.5%) and vomiting in 3 patients (9.4%). Twenty-seven patients were evaluable for response: one patient each had a complete response and a partial response for an overall response rate of 7.4%. The median time to progression was 3.3 months (95% confidence interval [CI], 1.6-3.7 months) and the median overall survival was 5.9 months (95% CI, 5.2-10.2 months). Conclusions: The combination of TMTX and CAP is well tolerated. However, recent studies have shown more active regimens in the second- and third-line metastatic setting. Copyright
Keyword Capecitabine
Colorectal cancer
Trimetrexate
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Unknown

Document type: Journal Article
Sub-type: Article (original research)
Collections: ResearcherID Downloads
Scopus Import
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 5 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 6 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sat, 09 Jul 2016, 04:03:46 EST by System User